Life sciences is moving beyond the lab and into a much broader public conversation. As breakthroughs in medicine, data and AI accelerate, the challenge is no longer simply making the science work. It’s making sure its meaning travels with it.
BioTechX Europe 2026 brings that changing landscape into sharp focus, gathering the global pharmaceutical and healthcare ecosystem at Messe Basel this October. Europe’s largest healthcare congress brings together advancements across medical discovery, data, AI and digital transformation. A session on quality of life as a real-world endpoint caught my eye. Amid extraordinary innovation and technical detail, it’s a reminder of what all this work is ultimately for: improving the lives of real people.
Whether a global pharmaceutical business or emerging biotech trailblazer, there’s a shared challenge behind the groundbreaking advances on show. Science may travel through trials, partnerships and healthcare systems into public view, but wider-world meaning and trust don’t always travel with it.
Modern medicine meets modern media
Healthcare audiences are broader than they used to be. During the pandemic, AstraZeneca, Pfizer and Moderna entered everyday conversation, sometimes controversially. Now medicines such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro are part of far-reaching discussions, altering perceptions and lifestyle choices around health, food, fashion and beauty.
The scale is striking. PwC estimates around three million UK adults currently use GLP-1 medicines, while Gallup suggests current use for weight loss equates to roughly 9% of the US population.
Patients, clinicians, policymakers and investors now scrutinise brands from many different directions all at once. Even a business selling chiefly to healthcare providers or governments may find its work featured in lifestyle coverage, patient communities, podcasts and social feeds. More people encounter its science, in fragments, without the context that gives the evidence meaning. That raises the stakes for how a company explains benefits, earns trust and behaves wherever people meet its brand across expanding touchpoints.
The corporate playbook is being rewritten
For pioneering Biotech or MedTech firms, the transition from a controlled lab setting into the public arena is a cultural shock. Previous audiences were mostly hyper-technical, spanning for example molecular biologists and venture capitalists. Communications commonly amounted to dense data spreads, peer reviews, polished PowerPoint decks, and possibly a trade press release.
Nowadays, these brands must navigate a complex omnichannel landscape that can encompass standalone custom web platforms, 3D digital animations, broader PR channels, patient advocacy platforms, data-compliant investor relations hubs and more. Even companies selling primarily to healthcare providers or governments may need to drip feed consumer news cycles, social media feeds and podcasts.
To thrive in this environment, companies must address two primary brand issues. The first is to put a human face to complex science without blurring the facts, expressing its meaning to real lives. The second is to give a growing portfolio a clear structure, with names and propositions that help each new offer add value to the company behind it.
Translating data into hope
Partners and investors need to see the evidence, opportunity and path ahead. Clinicians and patient communities need to understand what a development could mean in practice and what hasn’t yet been proved. Clear language matters, but so does a distinct position that makes the work memorable and its human purpose tangible.
Our work for Beacon Therapeutics began with pioneering retinal gene therapy and people facing sight loss. We built its name and brand around hope, then carried that thinking into a website with high-contrast colours and customisable font sizes. The story and the digital experience worked together, making a specialised field more accessible while respecting the seriousness of its science.
The same principle applies behind the scenes of care. mymediset’s SAP-native platform tracks surgical kits and inventory in real time. We shaped “Real Intelligence” as a proposition that connects technical capability to the practical stakes of getting the right equipment to the right operating room at the right time. The brand makes performance clear to decision-makers while keeping the people who depend on it in view.
Giving every innovation its place
Growth creates another kind of complexity. Over time, a growing category portfolio can become harder to understand from the outside and harder to manage from within.
Consider Eli Lilly’s expanding cardiometabolic category. Foundayo is an oral weight-management medicine joining a portfolio alongside Mounjaro. They’re different medicines with distinct formats and indications. Each needs a clear role within the wider Lilly story without suggesting the treatments are interchangeable.
Brand architecture provides that map. It defines what the parent company stands for, where individual products need their own identity and how the parts add up. That clarity matters in a partner presentation, a procurement process, a careers page or a patient-facing portal.
Beacon Therapeutics’ leadership actively utilised its new brand as an internal anchor to integrate legacy company cultures while giving external markets a clear link to its global ophthalmology mission.
Clarity with character compels confidence
Clinical evidence, regulatory rigour and access to care remain unequivocal foundations. But brand helps those strengths travel. Different audiences need different levels of detail and different experiences, with every claim grounded in the evidence and appropriate to its channel.
Strategic clarity makes a complex business easier to assess. Distinctive identity makes it easier to recognise. A coherent experience gives people more reason to trust what they see.
Make the science legible. Make the human benefit tangible. Unify the growth story.
At Dusted, we simplify complex businesses to make them salient and distinct. If your science is moving into a bigger commercial or public conversation, we can give it the clarity and character to lead. Explore our branding for health and life sciences.
Simplify complexity.
Talk to us if your science is moving beyond the lab – let’s make its value clear.
Follow Dusted for more thinking on how brand helps biotech and medtech businesses bring their science to a wider world. And subscribe to our newsletter for curated insights and thought leadership straight to your inbox.